Glenmark Pharmaceuticals Ltd. is a research-driven, global, integrated pharmaceutical company.
Glenmark is a leading player in the discovery of new molecules, both NCEs (new chemical entity) and NBEs (new biological entity), with seven molecules in various stages of clinical development & pre-clinical development. The company has a significant presence in branded generics markets across emerging economies including India. It's subsidiary, Glenmark Generics Limited has a fast growing and robust US generics business. The subsidiary also markets APIs to regulated and semi-regulated countries. Glenmark employs over 10,400 people in over 80 countries. It has 14 manufacturing facilities in four countries and has 6 R&D centres.
Since getting listed on the stock exchange in 2000, when Glenmark registered revenue of USD 32 Mn, the company is currently ranked among the World's top 100 Pharma & Biotech companies*. Recently, Glenmark has been chosen as the 'Best Company Across Emerging Markets' 2011, and recognized for the 'Best Overall Pipeline' 2011 by SCRIP, the largest selling and most respected pharmaceutical magazine in the world. SCRIP had also recognized Glenmark as 'Best Pharma Company in the World – SME' and 'Best Company in an Emerging Market' in 2008.
Other awards and recognitions received by the company include the "Best under a Billion Dollar companies in Asia" for 2008 by Forbes, a leading international publication, "Indian Innovator Pharmaceutical Company of the Year - 2010" by Frost & Sullivan, and Gold Patent Award 2011 in the categories of API Formulations & Export of bulk drugs (Non Biologicals) by Pharmexcil.
To emerge as a leading integrated research – based global pharmaceutical company
Achivement: We value achivement of objectives and consistently strive towards our Vision, with perseverence
Respect: We respect all stakeholders
Knowledge: We value knowledge such that it empowers our people to find innovative solutions to manage change
Speciality Business: Drug Discovery
Glenmark's ground-breaking drug discovery effort is primarily focused in the areas of inflammation (asthma/COPD, rheumatoid arthritis etc.), metabolic disorders (diabetes, obesity, etc.) and pain (neuropathic pain and inflammatory pain). Glenmark has A robust pipeline of 7 molecules – 4 NCEs and 3 NBEs in various stages of preclinical and preclinical development. Of these, five molecules are in clinical trials. The molecules in clinical development are focusing on advanced treatments for chronic/debilitating diseases and are potential blockbusters with potential peak sales opportunity for each molecule being in the range of USD 1 billion to 3 billion.
Simultaneously, Glenmark has actively followed the strategy of out-licensing its molecules in clinical development to large multinational pharmaceutical organizations. This outlicensing strategy has been successful so far with seven deals struck by the organization in the last nine years collecting USD 206 mn as upfront and milestone payments.
This business has three dedicated R&D centres. Discovery research for New Chemical Entities (NCEs) is carried out at its state-of-the-art research centre at Navi Mumbai, India. It is a complete end to end setup with expertise in all areas of NCE (new chemical entity) discovery and development ranging from target selection to clinical development. The centre boasts of a large number of highly qualified scientists.
Glenmark's biopharmaceutical research is carried out at its R&D facility in Switzerland. The centre is dedicated to the discovery and development of novel monoclonal antibodies (mAbs). The R&D centre has capabilities to develop mAbs from inception through to preclinical and clinical studies.
Glenmark has also invested in another state-of-the-art R&D facility in Oxford, UK for molecules in clinical development. The R&D facility serves as Glenmark's global centre for clinical development for both small molecules (NCEs) and biologics (NBEs).
Speciality Business: Formulations Businesses
Glenmark's formulations business is currently organized around four regions – India, Latin America, Central Eastern Europe and Semi Regulated Markets of Africa/Asia/CIS. The formulations business focuses on therapeutic areas viz. dermatology, anti-infectives, respiratory, cardiac, diabetes, gynecology, CNS, and oncology. India is the largest market in terms of revenue for the organization. The formulations business has six manufacturing facilities; four in India and two overseas. These facilities are approved by several regulatory bodies. The facility at Baddi, Himachal Pradesh, India is also approved by MHRA and USFDA for semi-solids. The overseas facilities are situated in Brazil and the Czech Republic. While the manufacturing facility in Brazil services requirements of the Latin American region, the Czech facility services requirements of the Central Eastern Europe region.
Glenmark has also invested in a dedicated R&D facility for formulations development. This R&D centre, situated near Nasik, India is engaged in developing specialty/ branded formulations for global markets.
Gienmark Generics LTD
Driven by its vision of becoming a leading global generics organization, Glenmark Generics Ltd. (GGL) has structured its businesses as US Generics, European Generics, the Active Pharmaceutical Ingredient (API) business and the Oncology Business. A subsidiary of Glenmark Pharmaceuticals Limited, GGL focuses on developing, manufacturing, selling and the distribution of generics through wholesalers, retailers and pharmacy chains. From APIs to front end marketing capabilities, GGL's businesses are vertically integrated into the generics market, by focusing on key niche segments including Dermatology, Hormones, Controlled Substances, Oncology and Modified Release Products.
At Glenmark, people are a cornerstone resource and success factor in driving business.
Glenmark focuses on enriching the lives of employees by providing them a supportive learning environment. Glenmark's Centre for Learning drives various Learning and Development initiatives and is a catalyst that champions change through its Organizational Development activities.
Glenmark provides benefits to all full-time employees, and their family dependents, at zero cost to the employee.
I have been working at Glenmark Generics USA full-time (more than a year)Approves of CEOApproves of CEO
It is a smaller conpany therefore you are able to work on many projects with a number departments. Its a great opportunity to gain experience quickly.
Leadership is new and they are still working out some of the kinks, but there is motivation to improve and to grow the company
Getting an Interview
Getting an Interview
- Accepted OfferPositive ExperienceDifficult InterviewAccepted OfferPositive ExperienceDifficult Interview
I applied through a recruiter. The process took 2 weeks – interviewed at Glenmark Generics USA (Mumbai (India)) in September 2011.
To the point, straight, Functional Competence
Yes, very fair company
Glenmark Generics USA aims to be a global integrated Generic and API leader. The Company currently markets finished dose formulations in USA, Europe, and Argentina and has Active Pharmaceutical Ingredients (APIs) presence in over 80 countries through an established group of subsidiaries, marketing front-ends and offices in India and select overseas locations.
GGL has a...
To emerge as a leading integrated research–based global pharmaceutical company
We value achievement of objectives and...